Wire · opportunities
NICE rebuffs Gilead's twice-yearly PrEP option
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
NICE in England has issued draft guidance recommending against NHS coverage of Gilead's twice-yearly injectable HIV PrEP drug lenacapavir due to uncertainties in clinical evidence and cost-effectiveness, despite UK regulatory approval. The decision considers availability of alternative PrEP options like oral generics and GSK's injectable cabotegravir and remains under review with a final decision expected after further consultation.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You face a narrow NHS market for injectable HIV prevention until Gilead adjusts pricing or evidence strengthens; pushing private or alternative NHS pathways could win access before NICE reverses. This is a clear pricing-driven access gate that shapes how new HIV prevention drugs enter the UK health system.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics